Clinical Trial Detail

NCT ID NCT01816984
Title PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Chicago
Indications

head and neck squamous cell carcinoma

Therapies

Cetuximab

Buparlisib

Age Groups: adult

No variant requirements are available.